National Drug Authority · Uganda
DEA-UG-2018-54780957
Tier 1 · Regulator-publishedUnclassifiedSafety communicationStatus · activeNot shown in search engines
- Issuing authority
- National Drug Authority (NDA)
- Authority reference
- 128/NDA/DPS/02/2018
- Date issued
- 15 Feb 2018Read from the archived document: printed date '15th February 2018', read from the scan by a person. The circulars page states no date, and the month shown as uploaded is when the file reached the Authority's website.
- Recorded by us
- 2026-09-09 22:24:19 UTC
- Notice
- Risk of hypersensitivity reaction in infants and children following administration of Nevirapine
- INN / active substance
- Not stated by the issuing authority
- Dosage form
- Not stated by the issuing authority
- Strength
- Not stated by the issuing authority
- Manufacturer
- Not stated by the issuing authority
- Manufacturer country
- Not stated by the issuing authority
- MAH or importer
- Not stated by the issuing authority
- Batch numbers
- Not published with the notice
- Expiry dates
- Not published with the notice
- Action type
- Safety communication
- Classification
- Not stated by the issuing authority
- Indicative severity
- Not assessed by Drug Eye Africa
- Defect category
- Not stated by the issuing authority
- Product type
- Medicine
- ATC code
- Not stated by the issuing authority
- Affected markets
- Uganda — no market beyond the issuing country was named on the notice
- Cross-border event
- Not linked to a cross-border event
- Notice text
- Not captured. The notice itself is linked below.
- Status
- Active
- Superseded by
- Not superseded. This is the current version.
- Version
- 12
Where this record came from, and what is held to show it.
- Primary source
- https://www.nda.or.ug/wp-content/uploads/2022/02/REACTION-OF-NEVIRAPINE-IN-CHILDREN1.pdf
- Copy of the source
- Taken and held by Drug Eye Africa, so the record survives the link above being moved or withdrawn. Not yet published at an address you can open.Ask us for it and check it against the fingerprint below.
- Fingerprint
- 9e4221bd8fdbe296b9b267d89230804b9d9a0401d5889687661f247c0cbcc3a9SHA-256 of the copy held. Any file that produces this number is that copy, byte for byte; any file that does not is a different document.
- Copy taken
- 2026-09-09 22:24:54 UTC
Cite this record
Drug Eye Africa (2018). DEA-UG-2018-54780957: Risk of hypersensitivity reaction in infants and children following administration of Nevirapine — Safety communication, National Drug Authority. Register of African Regulatory Actions. https://drugeyeafrica.org/register/notice/ug/2018/dea-ug-2018-54780957Version history
—No version history recorded for this record.
—Corrections appear here and in the site-wide log. Records are superseded, never deleted.
Verification
Tier 1 — Published by the issuing regulator on its own channel and captured by Drug Eye Africa, with the source document archived.
Indexing
This record is kept out of search engines, because the notice carries neither a batch number nor a stated reason. That lasts until the missing part is filled in. The record is held here in full in the meantime, and is found by searching this site.